Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study

References

• Rathore AS. Follow-on protein products: scientific issues, developments and challenges. Trends Biotechnol. 2009;27(12):698–705. doi:10.1016/j.tibtech.2009.09.004. PMID:19846228.
   PubMed Web of Science ®Google Scholar
• Mazur MT, Seipert RS, Mahon D, Zhou Q, Liu T. A platform for characterizing therapeutic monoclonal antibody breakdown products by 2D chromatography and top-down mass spectrometry. AAPS J. 2012;14(3):530–541. doi:10.1208/s12248-012-9361-6. PMID:22581105.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014 (http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf)
   Google Scholar
• Desanvicente-Celis Z, Caro-Moreno J, Enciso-Zuluaga M, Anaya JM. Similar biotherapeutic products in Latin America. Regulation and opportunities for patients with autoimmune diseases. Biosimilars. 2013;3:1–17.
   Google Scholar
• Nupur N, Singh SK, Narula G, Rathore AS. Assessing analytical comparability of biosimilars: GCSF as a case study. J Chromatography B. 2016;1032:165–171. doi:10.1016/j.jchromb.2016.05.027.
   PubMed Web of Science ®Google Scholar
• Schellekens H, Moors E. Clinical comparability and European biosimilar regulations. Nat Biotechnol. 2010; 28(1):28. doi:10.1038/nbt0110-28. PMID:20062035.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency CHMP. Concept paper on the revision of the guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant granulocyte-colony stimulating factor. 2015 (http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/07/WC500190635.pdf)
   Google Scholar
• U.S. FDA, Department of Health and Human Services. Guidance for Industry: Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product (Draft). 2016 (https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm397017.pdf)
   Google Scholar
• World Health Organization. Draft guidelines on evaluation of monoclonal antibodies as similar biotherapeutic products (SBPs). 2016 (http://www.who.int/biologicals/mAb_1st_draft_KG_IK_1_March_2016_clean.pdf)
   Google Scholar
• Singh V, Gupta D, Almasan A. Development of novel anti-CD20 monoclonal antibodies and modulation in CD20 levels on cell surface: looking to improve immunotherapy response. J Cancer Sci Therapy. 2015;7(11):347–358. doi:10.4172/1948-5956.1000373.
   PubMedGoogle Scholar
• IMGT Repertoire (IG and TR). Monoclonal antibodies with clinical indications (http://www.imgt.org/IMGTrepertoire/GenesClinical/monoclonalantibodies/#rituximab)
   Google Scholar
• Flores-Ortiz LF, Campos-García VR, Perdomo-Abúndez FC, Pérez NO, Medina-Rivero E. Physicochemical properties of Rituximab. J Liquid Chromatography Related Technologies. 2014;37(10):1438–1452. doi:10.1080/10826076.2013.794738.
   Web of Science ®Google Scholar
• Beck A, Diemer H, Ayoub D, Debaene F, Wagner-Rousset E, Carapito C, Van Dorsselaer A, Sanglier-Cianférani S. Analytical characterization of biosimilar antibodies and Fc-fusion proteins. Trends Analytical Chem. 2013;48:81–95. doi:10.1016/j.trac.2013.02.014.
   Web of Science ®Google Scholar
• Miranda-Hernández MP, López-Morales CA, Ramírez-Ibáñez ND, Piña-Lara N, Pérez NO, Molina-Pérez A, Revilla-Beltri J, Flores-Ortiz LF, Medina-Rivero E. Assessment of physicochemical properties of rituximab related to its immunomodulatory activity. J Immunol Res. 2015;2015:910763. doi:10.1155/2015/910763. PMID:25973441.
   PubMed Web of Science ®Google Scholar
• Guideline on similar biologics: Regulatory requirements for marketing authorization in India. Department Biotechnol Govt. India. 2012 (http://cdsco.nic.in/writereaddata/Bio%20Similar%20Guideline.pdf)
   Google Scholar
• Guideline IHT. Comparability of biotechnological/biological products subject to changes in their manufacturing process Q5E. 2004 (http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_Guideline.pdf)
   Google Scholar
• Guideline IHT. Specifications: Test procedures and acceptance criteria for Biological product Q6B. 1999 (http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q6B/Step4/Q6B_Guideline.pdf)
   Google Scholar
• Visser J, Feuerstein I, Stangler T, Schmiederer T, Fritsch C, Schiestl M. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. BioDrugs. 2013;27(5):495–507. doi:10.1007/s40259-013-0036-3. PMID:23649935.
   PubMed Web of Science ®Google Scholar
• Dorvignit D, Palacios JL, Merino M, Hernández T, Sosa K, Casacó A, López-Requena A, Mateo de Acosta C. Expression and biological characterization of an anti-CD20 biosimilar candidate antibody: a case study. MAbs. 2012;4(4):488–496. doi:10.4161/mabs.20761. PMID:22647435.
   PubMed Web of Science ®Google Scholar
• Montacir O, Montacir H, Eravci M, Springer A, Hinderlich S, Saadati A, Parr MK. Comparability study of Rituximab originator and follow-on biopharmaceutical. J Pharmaceutical Biomed Analysis. 2017;140:239–251. doi:10.1016/j.jpba.2017.03.029.
   PubMed Web of Science ®Google Scholar
• Cuello HA, Segatori VI, Alberto M, Pesce A, Alonso DF, Gabri MR. Comparability of antibody-mediated cell killing activity between a proposed biosimilar RTXM83 and the originator Rituximab. BioDrugs. 2016;30(3):225–231. doi:10.1007/s40259-016-0171-8. PMID:27053342.
   PubMed Web of Science ®Google Scholar
• Li C, Rossomando A, Wu SL, Karger BL. Comparability analysis of anti-CD20 commercial (rituximab) and RNAi-mediated fucosylated antibodies by two LC-MS approaches. MAbs. 2013;5(4):565–575. doi:10.4161/mabs.24814. PMID:23751726.
   PubMed Web of Science ®Google Scholar
• GaBI Online. Biosimilars of rituximab. Mol, Belgium: Pro Pharma Communications International. 2015 (http://www.gabionline.net/Biosimilars/General/Biosimilars-of-rituximab) [accessed on August 2017]
   Google Scholar
• Liao JJ, Darken PF. Comparability of critical quality attributes for establishing biosimilarity. Statistics Med. 2013;32(3):462–469. doi:10.1002/sim.5564.
   PubMed Web of Science ®Google Scholar
• Dolan JW. How much retention time variation is normal? LCGC North Am. 2014;32(8):546–551.
   Web of Science ®Google Scholar
• Varshavsky A. The N-end rule: functions, mysteries, uses. Proc Natl Acad Sci. 1996;93(22):12142–12149. doi:10.1073/pnas.93.22.12142. PMID:8901547.
   PubMed Web of Science ®Google Scholar
• Raju TS, Jordan RE. Galactosylation variations in marketed therapeutic antibodies. MAbs. 2012;4(3):385–391. doi:10.4161/mabs.19868. PMID:22531450.
   PubMed Web of Science ®Google Scholar
• Yang H, Yang S, Kong J, Dong A, Yu S. Obtaining information about protein secondary structures in aqueous solution using Fourier transform IR spectroscopy. Nat Protocols. 2015;10(3):382–396. doi:10.1038/nprot.2015.024. PMID:25654756.
   PubMed Web of Science ®Google Scholar
• Matheus S, Friess W, Mahler HC. FTIR and nDSC as analytical tools for high-concentration protein formulations. Pharmaceutical Res. 2006;23(6):1350–1363. doi:10.1007/s11095-006-0142-8.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency, CHMP. Guideline on development, production, characterization and specifications for monoclonal antibodies and related products. 2008 (http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/08/WC500211640.pdf)
   Google Scholar
• Arosio P, Barolo G, Müller-Späth T, Wu H, Morbidelli M. Aggregation stability of a monoclonal antibody during downstream processing. Pharmaceutical Res. 2011; 28(8):1884–1894. doi:10.1007/s11095-011-0416-7.
   PubMed Web of Science ®Google Scholar
• Joshi V, Kumar V, Rathore AS. Rapid analysis of charge variants of monoclonal antibodies using non-linear salt gradient in cation-exchange high performance liquid chromatography. J Chromatography A. 2015;1406:175–185. doi:10.1016/j.chroma.2015.06.015.
   PubMed Web of Science ®Google Scholar
• Singh SK, Narula G, Rathore AS. Should charge variants of monoclonal antibody therapeutics be considered critical quality attributes? Electrophoresis. 2016;37(17–18):2338–2346. doi:10.1002/elps.201600078. PMID:27387433.
   PubMed Web of Science ®Google Scholar
• Lyubarskaya Y, Houde D, Woodard J, Murphy D, Mhatre R. Analysis of recombinant monoclonal antibody isoforms by electrospray ionization mass spectrometry as a strategy for streamlining characterization of recombinant monoclonal antibody charge heterogeneity. Analytical Biochem. 2006;348(1):24–39. doi:10.1016/j.ab.2005.10.003.
   PubMed Web of Science ®Google Scholar
• Du Y, Walsh A, Ehrick R, Xu W, May K, Liu H. Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies. MAbs. 2012;4(5):578–585. doi:10.4161/mabs.21328. PMID:22820257.
   PubMed Web of Science ®Google Scholar
• Alsenaidy MA, Jain NK, Kim JH, Middaugh CR, Volkin DB. Protein comparability assessments and potential applicability of high throughput biophysical methods and data visualization tools to compare physical stability profiles. Frontiers Pharmacol. 2014;5:39. doi:10.3389/fphar.2014.00039.
   PubMed Web of Science ®Google Scholar
• Guideline IHT. Quality of biotechnological products: Stability testing of biotechnological/biological products Q5C. 1995 (http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5C/Step4/Q5C_Guideline.pdf)
   Google Scholar
• Liu H, Gaza-Bulseco G, Sun J. Characterization of the stability of a fully human monoclonal IgG after prolonged incubation at elevated temperature. J Chromatography B. 2006;837(1):35–43. doi:10.1016/j.jchromb.2006.03.053.
   PubMed Web of Science ®Google Scholar
• Rafiq S, Butchar JP, Cheney C, Mo X, Trotta R, Caligiuri M, Jarjoura D, Tridandapani S, Muthusamy N, Byrd JC. Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. J Immunol. 2013;190(6):2702–2711. doi:10.4049/jimmunol.1202588. PMID:23418626.
   PubMed Web of Science ®Google Scholar
• Bowles JA, Wang SY, Link BK, Allan B, Beuerlein G, Campbell MA, Marquis D, Ondek B, Wooldridge JE, Smith BJ, et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood. 2006;108(8):2648–2654. doi:10.1182/blood-2006-04-020057. PMID:16825493.
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood. 2002;99(3):754–758. doi:10.1182/blood.V99.3.754. PMID:11806974.
   PubMed Web of Science ®Google Scholar
• Weiner GJ. Rituximab: mechanism of action. Seminars Hematol. 2010;47(2):115–123. doi:10.1053/j.seminhematol.2010.01.011.
   PubMed Web of Science ®Google Scholar
• Zhou X, Hu W, Qin X. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist. 2008;13(9):954–966. doi:10.1634/theoncologist.2008-0089. PMID:18779537.
   PubMed Web of Science ®Google Scholar
• Natsume A, Niwa R, Satoh M. Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC. Drug Design Dev Therapy. 2009;3:7.
   PubMed Web of Science ®Google Scholar
• Du J, Wang H, Zhong C, Peng B, Zhang M, Li B, Huo S, Guo Y, Ding J. Structural basis for recognition of CD20 by therapeutic antibody Rituximab. J Biol Chem. 2007;282(20):15073–15080. doi:10.1074/jbc.M701654200. PMID:17395584.
   PubMed Web of Science ®Google Scholar
• Tsiftsoglou AS, Ruiz S, Schneider CK. Development and regulation of biosimilars: current status and future challenges. BioDrugs. 2013;27(3):203–211. doi:10.1007/s40259-013-0020-y. PMID:23553340.
   PubMed Web of Science ®Google Scholar
• Schellekens H. How similar do ‘biosimilars' need to be? Nat Biotechnol. 2004;22(11):1357–1359. doi:10.1038/nbt1104-1357. PMID:15529154.
   PubMed Web of Science ®Google Scholar
• Schellekens H. Assessing the bioequivalence of biosimilars: the Retacrit® case. Drug Discovery Today. 2009;14(9):495–499. doi:10.1016/j.drudis.2009.02.003. PMID:19429509.
   PubMed Web of Science ®Google Scholar
• Jacobs I, Singh E, Sewell KL, AL-Sabbagh A, Shane LG. Patient attitudes and understanding about biosimilars: an international cross-sectional survey. Patient Preference Adherence. 2016;10:937. doi:10.2147/PPA.S104891. PMID:27307714.
   PubMed Web of Science ®Google Scholar
• Eon‐Duval A, Broly H, Gleixner R. Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach. Biotechnol Progress. 2012;28(3):608–622. doi:10.1002/btpr.1548.
   PubMed Web of Science ®Google Scholar
• Xie H, Chakraborty A, Ahn J, Yu YQ, Dakshinamoorthy DP, Gilar M, Chen W, Skilton SJ, Mazzeo JR. Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies. MAbs. 2010;2(4):379–394. doi:10.4161/mabs.11986. PMID:20458189.
   PubMed Web of Science ®Google Scholar
• Park SS, Park J, Ko J, Chen L, Meriage D, Crouse‐Zeineddini J, Wong W, Kerwin BA. Biochemical assessment of erythropoietin products from Asia versus US Epoetin alfa manufactured by Amgen. J Pharmaceutical Sci. 2009; 98(5):1688–1699. doi:10.1002/jps.21546.
   PubMed Web of Science ®Google Scholar
• Ayoub D, Jabs W, Resemann A, Evers W, Evans C, Main L, Baessmann C, Wagner-Rousset E, Suckau D, Beck A. Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques. MAbs. 2013;5(5):699–710. doi:10.4161/mabs.25423. PMID:23924801.
   PubMed Web of Science ®Google Scholar
• Liu J, Eris T, Li C, Cao S, Kuhns S. Assessing analytical similarity of proposed Amgen biosimilar ABP 501 to adalimumab. BioDrugs. 2016;30(4):321–338. doi:10.1007/s40259-016-0184-3. PMID:27461107.
   PubMed Web of Science ®Google Scholar
• Jung SK, Lee KH, Jeon JW, Lee JW, Kwon BO, Kim YJ, Bae JS, Kim DI, Lee SY, Chang SJ. Physicochemical characterization of Remsima®. MAbs. 2014;6(5):1163–1177. doi:10.4161/mabs.32221. PMID:25517302.
   PubMed Web of Science ®Google Scholar
• da Silva A, Kronthaler U, Koppenburg V, Fink M, Meyer I, Papandrikopoulou A, Hofmann M, Stangler T, Visser J. Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013. Leukemia Lymphoma. 2014;55(7):1609–1617. doi:10.3109/10428194.2013.843090. PMID:24024472.
   PubMed Web of Science ®Google Scholar
• Miranda-Hernández MP, López-Morales CA, Piña-Lara N, Perdomo-Abúndez FC, Pérez NO, Revilla-Beltri J, Molina-Pérez A, Estrada-Marín L, Flores-Ortiz LF, Ruiz-Argüelles A, et al. Pharmacokinetic comparability of a biosimilar trastuzumab anticipated from its physicochemical and biological characterization. BioMed Res Int. 2015;2015:874916. doi:10.1155/2015/874916. PMID:26682224.
   PubMed Web of Science ®Google Scholar
• Velayudhan J, Chen YF, Rohrbach A, Pastula C, Maher G, Thomas H, Brown R, Born TL. Demonstration of functional similarity of proposed biosimilar ABP 501 to adalimumab. BioDrugs. 2016;30(4):339–351. doi:10.1007/s40259-016-0185-2. PMID:27422671.
   PubMed Web of Science ®Google Scholar
• Schiestl M, Stangler T, Torella C, Čepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011;29(4):310–312. doi:10.1038/nbt.1839. PMID:21478841.
   PubMed Web of Science ®Google Scholar
• Chelius D, Jing K, Lueras A, Rehder DS, Dillon TM, Vizel A, Rajan RS, Li T, Treuheit MJ, Bondarenko PV. Formation of pyroglutamic acid from N-terminal glutamic acid in immunoglobulin gamma antibodies. Analytical Chem. 2006;78(7):2370–2376. doi:10.1021/ac051827k.
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 2006;313(5787):670–673. doi:10.1126/science.1129594. PMID:16888140.
   PubMed Web of Science ®Google Scholar
• Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K, Chung S, Strouse R, Mire-Sluis A, Schenerman M. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discovery. 2011;10(2):101. doi:10.1038/nrd3365. PMID:21283105.
   PubMed Web of Science ®Google Scholar
• Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida K, Kakita S, Tsumoto K, Kumagai I, Shitara K. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcγRIIIa. J Mol Biol. 2004;336(5):1239–1249. doi:10.1016/j.jmb.2004.01.007. PMID:15037082.
   PubMed Web of Science ®Google Scholar
• Yu M, Brown D, Reed C, Chung S, Lutman J, Stefanich E, Wong A, Stephan JP, Bayer R. Production, characterization and pharmacokinetic properties of antibodies with N-linked Mannose-5 glycans. MAbs. 2012;4(4):475–487. doi:10.4161/mabs.20737. PMID:22699308.
   PubMed Web of Science ®Google Scholar
• Reusch D, Tejada ML. Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology. 2015;25(12):1325–1334. doi:10.1093/glycob/cwv065. PMID:26263923.
   PubMed Web of Science ®Google Scholar
• Ferrara C, Grau S, Jäger C, Sondermann P, Brünker P, Waldhauer I, Hennig M, Ruf A, Rufer AC, Stihle M, et al. Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose. Proc Natl Acad Sci. 2011;108(31):12669–74 doi:10.1073/pnas.1108455108. PMID:21768335.
   PubMed Web of Science ®Google Scholar
• Yu L, Vizel A, Huff MB, Young M, Remmele RL, He B. Investigation of N-terminal glutamate cyclization of recombinant monoclonal antibody in formulation development. J Pharmaceutical Biomed Analysis. 2006;42(4):455–63. doi:10.1016/j.jpba.2006.05.008.
   PubMed Web of Science ®Google Scholar
• Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J. 2006;8(3):E501–E507. doi:10.1208/aapsj080359. PMID:17025268.
   PubMed Web of Science ®Google Scholar
• Wang W, Singh S, Zeng DL, King K, Nema S. Antibody structure, instability, and formulation. J Pharmaceutical Sci. 2007;96(1):1–26. doi:10.1002/jps.20727.
   PubMed Web of Science ®Google Scholar
• Joshi V, Shivach T, Yadav N, Rathore AS. Circular dichroism spectroscopy as a tool for monitoring aggregation in monoclonal antibody therapeutics. Analytical Chem. 2014;86(23):11606–13. doi:10.1021/ac503140j.
   PubMed Web of Science ®Google Scholar
• Rubinstein M, Colby RH. Polymer physics. New York: Oxford University Press; 2003.
   Google Scholar